Phase 3 trial data point to more options for patients with relapsed or refractory multiple myeloma
This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, a phase 3 trial showed that the BCMA‐targeting bispecific antibody teclistamab significantly improved progression‐free survival and overall survival in patients with relapsed or refractory multiple myeloma who received one to three previous lines of therapy. In addition, adjuvant nivolumab fails to improve disease‐free survival in patients with resected NSCLC, and perioperative apalutamide plus ADT presents a new option for high‐risk localized prostate cancer.
Authors
- Leah Lawrence
Publication Details
- Journal
- Cancer
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1002/cncr.70639
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00